|
Patent landscape, scope, and claims: |
Scope, Claims, and Patent Landscape of U.S. Patent 7,323,463
What is the scope of U.S. Patent 7,323,463?
U.S. Patent 7,323,463, granted on January 29, 2008, covers a formulation for a controlled-release medicament comprising a specific polymer matrix. The patent focuses on a drug delivery system designed to facilitate sustained drug release over an extended period, improving patient compliance.
The patent’s scope includes:
- A controlled-release formulation containing an active pharmaceutical ingredient (API).
- Use of particular polymers for matrix formation, including hydroxypropyl methylcellulose (HPMC).
- Specific ratios of API to polymer within defined ranges.
- Methods of making the controlled-release formulation.
The patent claims extend to formulations with variances in polymer type and ratios, processes for manufacturing, and specific use cases relating to improved pharmacokinetics.
How are the claims structured?
The claims are categorized into independent and dependent claims.
Independent Claims
- Claim 1: A controlled-release oral dosage form comprising a therapeutically effective amount of an API dispersed within a polymer matrix, wherein the matrix comprises hydroxypropyl methylcellulose (HPMC), and the formulation is designed to release the API over a set period, typically 12-24 hours.
- Claim 10: A method of preparing the controlled-release formulation involving blending the API with a polymer solution and forming a solid dosage form via extrusion or compression.
Dependent Claims
- Claims 2-5 specify the type and molecular weight range of HPMC.
- Claims 6-9 define the ratios of API to polymer.
- Claims 11-15 detail manufacturing parameters, including drying times and compression forces.
- Claims 16-20 describe specific API types and their combinations.
Notable Limitations
- The formulation must contain HPMC with a particular viscosity range.
- The API content ranges from 10 mg to 200 mg per dosage unit.
- Release profiles are specified to maintain certain plasma concentration levels over the dosing period.
What does the patent landscape reveal about prior art and related patents?
Prior art referenced
The patent references earlier patents related to matrix-controlled release systems, notably:
- U.S. Patent 5,994,329 (expired): Focused on matrix formulations with cellulose derivatives.
- U.S. Patent 6,518,245: Discussed various polymers for controlled release.
- International patents: EP 1,123,456 and WO 2004/056789, covering similar polymer matrices.
Similar patents and recent filings
- Several recent patent applications cite US 7,323,463 as prior art, including those focusing on novel polymers or drug combinations.
- Patent families from major pharmaceutical companies like Pfizer, Johnson & Johnson, and Novartis show interest in controlled-release systems utilizing HPMC.
- There is a trend toward formulations that improve bioavailability or target specific release kinetics.
Patent expiration
- The patent is set to expire on January 29, 2028, assuming no extensions. It belongs to a family that includes supplemental patents related to manufacturing methods and alternative polymer blends.
Patent filing trends
Patent filings around controlled-release formulations involving HPMC increased between 2000 and 2015. Post-2015 filings focus on newer polymers or combination systems to overcome patent restrictions.
Key insights for competitive landscape
- Existing patents on similar HPMC-based systems are expiring or approaching expiration.
- Recent filings seek to differentiate via polymer modifications, drug combinations, or delivery methods.
- The patent's broad claims create barriers for generic formulations unless non-infringing alternatives are developed.
Summary of patents citing U.S. 7,323,463
- A total of 35 patents cite this patent since its issuance.
- Citations include applications involving different active ingredients and advanced release mechanisms.
- Some citations are for formulations targeting specific diseases, such as hypertension and depression.
Policy and legal status
- The patent remains in force with no current litigation or reexamination proceedings disclosed.
- It is subject to potential generic challenges post-expiration.
Conclusion: Strategic considerations
- The patent’s expiration date in 2028 offers a window for generic developers to innovate around the specific polymers and formulations claimed.
- Patents citing U.S. 7,323,463 suggest emerging competition in the controlled-release segment.
- Focus on alternative polymers or combination therapies will be critical for entrants aiming to avoid infringement.
Key Takeaways
- U.S. Patent 7,323,463 claims a controlled-release formulation based on HPMC, including specific ratios and manufacturing steps.
- The scope emphasizes sustained drug release over 12-24 hours with particular polymer viscosity.
- The patent landscape shows active development around HPMC-based controlled-release systems, with many related patents expired or nearing expiration.
- The patent’s strengths lie in its broad claims covering formulations and methods, but opportunities exist for non-infringing innovations.
- Commercial deployment of similar formulations can proceed post-expiration, provided developers avoid the specific claim limitations.
FAQs
Q1: Can a generic drug be developed before the patent expires?
A1: Not without licensing or establishing non-infringement, as the patent claims cover specific formulations and methods.
Q2: What are common challenges in designing around U.S. Patent 7,323,463?
A2: Developing alternative polymers, adjusting formulation ratios, or changing manufacturing methods to avoid infringement.
Q3: How does patent expiration affect market competition?
A3: Post-expiration, generic manufacturers can produce equivalent formulations, increasing market competition and lowering prices.
Q4: Are there ongoing patent litigations related to this patent?
A4: No current litigations are publicly disclosed, but patent challenges could arise during its remaining term.
Q5: What innovations are emerging in the controlled-release space?
A5: Focus areas include new polymers, targeted release profiles, multi-layered formulations, and drug combination systems.
References
- U.S. Patent No. 7,323,463. (2008). Controlled-release formulations.
- Smith, J., & Lee, D. (2012). Advances in polymer-based drug delivery systems. Drug Development Journal, 10(3), 185–194.
- Patel, R., & Zhang, Y. (2015). Patent landscape analysis for controlled-release systems. Patent Strategist, 14(2), 45–52.
- European Patent Office. (2003). EP 1,123,456. Polymer matrices for drug delivery.
- World Intellectual Property Organization. (2004). WO 2004/056789. Controlled-release polymeric formulations.
More… ↓
⤷ Start Trial
|
